State Street SPDR S&P Pharmaceuticals ETF XPH
Set alert
At close · Oct 30
After hours · Oct 30, 4:00 PM ET
- YTD
- +15.69%
- 1 year
- +31.41%
- Open
- 65.32
- Prev close
- 65.18
- Mkt cap
- 262.86M
- Vol
- 230.63K
- Avg vol
- 166.63K
- EPS
- 3.78
- P/E
- 17.13
- Div yield
- 0.00%
More statistics
- Low
- 64.44
- High
- 65.71
- Forward P/E
- 0.00
- Beta
- 0.00
- Short ratio
- 0.00
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 45.94
- 200-d avg
- 42.92
5D chart
Signals (105)
| Name | Time | Ago |
|---|---|---|
| SMA: Bullish | Oct 29, 11:20 AM | 2 days ago |
| SMA: Bearish | Oct 29, 10:50 AM | 2 days ago |
| MACD: Sell Signal | Oct 29, 10:40 AM | 2 days ago |
| RSI: Overbought | Oct 29, 9:30 AM | 2 days ago |
| MACD: Buy Signal | Oct 28, 3:35 PM | 3 days ago |
| SMA: Bullish | Oct 28, 3:30 PM | 3 days ago |
| SMA: Bullish | Oct 28, 3:30 PM | 3 days ago |
| SMA: Bearish | Oct 28, 3:15 PM | 3 days ago |
| MACD: Sell Signal | Oct 28, 2:55 PM | 3 days ago |
| SMA: Bearish | Oct 28, 2:50 PM | 3 days ago |
| SMA: Bullish | Oct 28, 2:30 PM | 3 days ago |
| MACD: Buy Signal | Oct 28, 2:30 PM | 3 days ago |
| SMA: Bearish | Oct 28, 2:25 PM | 3 days ago |
| MACD: Sell Signal | Oct 28, 2:25 PM | 3 days ago |
| MACD: Buy Signal | Oct 28, 2:20 PM | 3 days ago |
| SMA: Bullish | Oct 28, 2:15 PM | 3 days ago |
| SMA: Bullish | Oct 28, 2:15 PM | 3 days ago |
| MACD: Sell Signal | Oct 28, 2:05 PM | 3 days ago |
| SMA: Bearish | Oct 28, 2:00 PM | 3 days ago |
| MACD: Buy Signal | Oct 28, 1:15 PM | 3 days ago |
| SMA: Bullish | Oct 28, 1:10 PM | 3 days ago |
| SMA: Bearish | Oct 28, 1:00 PM | 3 days ago |
| SMA: Bullish | Oct 28, 12:55 PM | 3 days ago |
| SMA: Bullish | Oct 28, 12:40 PM | 3 days ago |
| MACD: Sell Signal | Oct 28, 11:50 AM | 3 days ago |
| SMA: Bullish | Oct 28, 11:15 AM | 3 days ago |
| SMA: Bearish | Oct 28, 11:05 AM | 3 days ago |
| MACD: Buy Signal | Oct 28, 10:25 AM | 3 days ago |
| MACD: Sell Signal | Oct 28, 10:20 AM | 3 days ago |
| MACD: Buy Signal | Oct 28, 10:05 AM | 3 days ago |
| SMA: Bullish | Oct 28, 9:55 AM | 3 days ago |
| SMA: Bullish | Oct 28, 9:55 AM | 3 days ago |
| SMA: Bearish | Oct 28, 9:30 AM | 3 days ago |
| SMA: Bearish | Oct 28, 9:30 AM | 3 days ago |
| MACD: Sell Signal | Oct 28, 9:30 AM | 3 days ago |
| MACD: Buy Signal | Oct 27, 3:45 PM | 4 days ago |
| RSI: Overbought | Oct 27, 3:40 PM | 4 days ago |
| MACD: Sell Signal | Oct 27, 3:35 PM | 4 days ago |
| RSI: Overbought | Oct 27, 3:05 PM | 4 days ago |
| MACD: Buy Signal | Oct 27, 2:45 PM | 4 days ago |
| MACD: Sell Signal | Oct 27, 2:35 PM | 4 days ago |
| SMA: Bullish | Oct 27, 2:05 PM | 4 days ago |
| MACD: Buy Signal | Oct 27, 2:05 PM | 4 days ago |
| MACD: Sell Signal | Oct 27, 2:00 PM | 4 days ago |
| SMA: Bearish | Oct 27, 1:55 PM | 4 days ago |
| MACD: Buy Signal | Oct 27, 1:35 PM | 4 days ago |
| SMA: Bullish | Oct 27, 1:25 PM | 4 days ago |
| SMA: Bearish | Oct 27, 1:20 PM | 4 days ago |
| SMA: Bullish | Oct 27, 1:10 PM | 4 days ago |
| SMA: Bullish | Oct 27, 1:10 PM | 4 days ago |
| MACD: Sell Signal | Oct 27, 11:55 AM | 4 days ago |
| SMA: Bullish | Oct 27, 11:40 AM | 4 days ago |
| RSI: Overbought | Oct 27, 10:50 AM | 4 days ago |
| SMA: Bullish | Oct 27, 10:35 AM | 4 days ago |
| SMA: Bearish | Oct 27, 10:20 AM | 4 days ago |
| SMA: Bullish | Oct 27, 10:10 AM | 4 days ago |
| SMA: Bullish | Oct 27, 10:10 AM | 4 days ago |
| SMA: Bearish | Oct 27, 10:00 AM | 4 days ago |
| SMA: Bearish | Oct 27, 10:00 AM | 4 days ago |
| SMA: Bullish | Oct 27, 9:40 AM | 4 days ago |
| SMA: Bullish | Oct 27, 9:40 AM | 4 days ago |
| SMA: Bearish | Oct 27, 9:30 AM | 4 days ago |
| MACD: Buy Signal | Oct 26, 3:55 PM | 5 days ago |
| SMA: Bullish | Oct 26, 3:45 PM | 5 days ago |
| SMA: Bearish | Oct 26, 3:40 PM | 5 days ago |
| SMA: Bullish | Oct 26, 3:35 PM | 5 days ago |
| SMA: Bearish | Oct 26, 3:00 PM | 5 days ago |
| MACD: Sell Signal | Oct 26, 3:00 PM | 5 days ago |
| RSI: Oversold | Oct 26, 3:00 PM | 5 days ago |
| MACD: Buy Signal | Oct 26, 2:40 PM | 5 days ago |
| SMA: Bullish | Oct 26, 2:15 PM | 5 days ago |
| SMA: Bearish | Oct 26, 1:50 PM | 5 days ago |
| SMA: Bullish | Oct 26, 1:30 PM | 5 days ago |
| SMA: Bearish | Oct 26, 12:45 PM | 5 days ago |
| SMA: Bearish | Oct 26, 12:45 PM | 5 days ago |
| MACD: Sell Signal | Oct 26, 12:45 PM | 5 days ago |
| MACD: Buy Signal | Oct 26, 12:20 PM | 5 days ago |
| SMA: Bullish | Oct 26, 12:05 PM | 5 days ago |
| SMA: Bearish | Oct 26, 12:00 PM | 5 days ago |
| SMA: Bullish | Oct 26, 11:55 AM | 5 days ago |
| SMA: Bullish | Oct 26, 11:55 AM | 5 days ago |
| SMA: Bearish | Oct 26, 11:50 AM | 5 days ago |
| SMA: Bearish | Oct 26, 11:45 AM | 5 days ago |
| SMA: Bearish | Oct 26, 11:30 AM | 5 days ago |
| MACD: Sell Signal | Oct 26, 11:30 AM | 5 days ago |
| MACD: Buy Signal | Oct 26, 11:20 AM | 5 days ago |
| SMA: Bearish | Oct 26, 10:40 AM | 5 days ago |
| MACD: Sell Signal | Oct 26, 10:40 AM | 5 days ago |
| RSI: Overbought | Oct 26, 10:10 AM | 5 days ago |
| RSI: Overbought | Oct 26, 9:35 AM | 5 days ago |
| SMA: Bullish | Oct 26, 9:30 AM | 5 days ago |
| RSI: Overbought | Oct 23, 3:40 PM | 1 week ago |
| SMA: Bullish | Oct 23, 2:50 PM | 1 week ago |
| SMA: Bullish | Oct 23, 2:35 PM | 1 week ago |
| SMA: Bearish | Oct 23, 1:35 PM | 1 week ago |
| SMA: Bullish | Oct 23, 1:30 PM | 1 week ago |
| SMA: Bullish | Oct 23, 1:30 PM | 1 week ago |
| SMA: Bearish | Oct 23, 12:55 PM | 1 week ago |
| SMA: Bullish | Oct 23, 12:45 PM | 1 week ago |
| MACD: Buy Signal | Oct 23, 12:45 PM | 1 week ago |
| RSI: Oversold | Oct 23, 12:25 PM | 1 week ago |
| SMA: Bearish | Oct 23, 11:35 AM | 1 week ago |
| SMA: Bullish | Oct 23, 11:20 AM | 1 week ago |
| SMA: Bearish | Oct 23, 11:00 AM | 1 week ago |
| SMA: Bullish | Oct 23, 10:50 AM | 1 week ago |
News
1 day ago fool.com
Can GLP-1s Fatten Your Portfolio? We Examine the VanEck Pharmaceutical ETF vs State Street SPDR Pharmaceuticals ETF
VanEck Pharmaceutical ETF provides a higher dividend yield and lower price volatility compared to the State Street fund. State Street SPDR Pharmaceuticals ETF offers a more diversified portfolio with…
5 days ago fool.com
Which Healthcare ETF Is the Better Buy: State Street's Pharma XPH or Simplify's Mission-Driven PINK?
State Street SPDR S&P Pharmaceuticals ETF offers a lower expense ratio but has a lower dividend yield than Simplify Health Care ETF. Simplify Health Care ETF has shown significantly lower maximum…
1 week ago zacks.com
Is State Street SPDR S&P Pharmaceuticals ETF (XPH) a Strong ETF Right Now?
The State Street SPDR S&P Pharmaceuticals ETF (XPH) made its debut on 06/19/2006, and is a smart beta exchange traded fund that provides broad exposure to the Health Care ETFs category of the market.
2 weeks ago seekingalpha.com
XPH: Healthcare Sector Dashboard For October
Pharmaceuticals/biotechnology are currently overvalued by 14% versus 11-year averages, while healthcare equipment appears undervalued despite recent value score deterioration. State Street SPDR S&P…
3 weeks ago fool.com
Better Pharma ETF: iShares IHE vs. State Street XPH
The iShares U.S. Pharmaceuticals ETF is significantly more concentrated than the State Street SPDR S&P Pharmaceuticals ETF, with Eli Lilly accounting for 23.63% of the portfolio. The iShares U.S.…
3 weeks ago fool.com
Better Healthcare ETF: VanEck's Biotech-Focused BBH vs. State Street's XPH Targeting Pharma
BBH concentrates on 25 large-cap biotech leaders, while XPH diversifies across 62 pharmaceutical holdings. Both charge 0.35% annually, but their five-year returns diverged significantly.
3 weeks ago zacks.com
Should You Invest in the State Street SPDR S&P Pharmaceuticals ETF (XPH)?
Designed to provide broad exposure to the Healthcare - Pharma segment of the equity market, the State Street SPDR S&P Pharmaceuticals ETF (XPH) is a passively managed exchange traded fund launched on…
3 weeks ago zacks.com
Execution of Pharma Tariffs Brings These ETFs Into Focus
Trump's 100% pharma tariff is reshaping the drug industry. Here's how the key pharma ETFs could be affected.
1 month ago defenseworld.net
SPDR S&P Pharmaceuticals ETF (NYSEARCA:XPH) Sees Large Volume Increase – Still a Buy?
SPDR S&P Pharmaceuticals ETF (NYSEARCA:XPH - Get Free Report) shares saw an uptick in trading volume on Monday. 145,914 shares changed hands during mid-day trading, an increase of 46% from the…
1 month ago defenseworld.net
Integrated Wealth Concepts LLC Buys Shares of 48,874 SPDR S&P Pharmaceuticals ETF $XPH
Integrated Wealth Concepts LLC purchased a new position in shares of SPDR S&P Pharmaceuticals ETF (NYSEARCA:XPH) in the undefined quarter, according to the company in its most recent filing with the…
1 month ago fool.com
IXJ vs XPH: Global Healthcare ETF or Pharma Focus?
iShares Global Healthcare ETF provides broad sector coverage with a higher dividend yield than State Street SPDR S&P Pharmaceuticals ETF. State Street SPDR S&P Pharmaceuticals ETF has delivered…
1 month ago fool.com
Better Healthcare ETF: Vanguard's VHT vs. State Street's Pharmaceuticals-Focused XPH
Vanguard's broader healthcare portfolio charges less and yields more, but State Street's pharma-focused fund has delivered stronger recent gains despite higher volatility.
1 month ago fool.com
Which Healthcare ETF Is the Better Buy: Fidelity's Broad FHLC or State Street's Pharma-Focused XPH?
FHLC captures the whole healthcare opportunity at rock-bottom cost. XPH narrows the bet to pharmaceuticals and charges significantly more for it.
2 months ago fool.com
XPH vs PJP: Which Pharma ETF Offers Better Value
The State Street SPDR S&P Pharmaceuticals ETF offers a significantly lower expense ratio of 0.35% compared to the Invesco Pharmaceuticals ETF. The Invesco Pharmaceuticals ETF provides a more…
2 months ago fool.com
Better Healthcare ETF: State Street's Pharmaceuticals-Focused XPH vs. Invesco's S&P 500-Targeted RSPH
The Invesco S&P 500 Equal Weight Health Care ETF provides broad exposure to the sector, while the State Street SPDR S&P Pharmaceuticals ETF focuses specifically on the pharmaceutical industry. The…
2 months ago zacks.com
Is State Street SPDR S&P Pharmaceuticals ETF (XPH) a Strong ETF Right Now?
The State Street SPDR S&P Pharmaceuticals ETF (XPH) made its debut on 06/19/2006, and is a smart beta exchange traded fund that provides broad exposure to the Health Care ETFs category of the market.
2 months ago zacks.com
Should You Invest in the State Street SPDR S&P Pharmaceuticals ETF (XPH)?
Launched on June 19, 2006, the State Street SPDR S&P Pharmaceuticals ETF (XPH) is a passively managed exchange traded fund designed to provide a broad exposure to the Healthcare - Pharma segment of…
3 months ago benzinga.com
Two Years to Build or Pay 200% — Which US Pharma Stocks Win?
Trump sets a 2-year ultimatum for generic drugmakers to reshore U.S. production or face tariffs up to 200%.
3 months ago etftrends.com
Healthcare Rules State Street's Top 5 ETFs in Past Month
With well over 170 ETFs on the market covering diverse investment strategies, State Street offers a prime window into which funds — and market trends — are leading the pack in the near term. Key…
3 months ago fool.com
Which Pharmaceuticals ETF Is Better, the iShares IHE or State Street XPH?
The iShares U.S. Pharmaceuticals ETF is larger by assets under management and offers a higher trailing dividend yield. The State Street SPDR S&P Pharmaceuticals ETF has delivered higher one-year…
3 months ago seekingalpha.com
XPH: Healthcare Dashboard For July
Pharmaceuticals/biotechnology valuations and quality are near 11-year historical baselines, while healthcare equipment appears undervalued and life science tools least attractive. State Street SPDR…
6 months ago benzinga.com
Why Is Organon Stock Skyrocketing Monday?
Sun Pharma to acquire Organon in an all-cash deal valued at $11.75 billion. OGN shares rise on the acquisition news.
6 months ago benzinga.com
Why Is Amneal Pharmaceuticals Stock Gaining Today?
Amneal Pharmaceuticals rises premarket after $1.1B Kashiv BioSciences deal to expand biosimilars platform and tap $300B biologics opportunity, while raising FY26 outlook.
7 months ago benzinga.com
Axsome Stock Climbs On Schizophrenia Drug Deal With Takeda
Axsome gains after securing global rights to balipodect from Takeda, advancing schizophrenia pipeline amid bullish analyst targets.
7 months ago benzinga.com
Prestige Bets $1 Billion On World's Most Iconic Nasal Strip
Prestige Consumer Healthcare acquires Breathe Right brand for $1.045 billion. Deal expands OTC portfolio into sleep & breathing categories.
9 months ago benzinga.com
Trump Unveils 'Great Healthcare Plan,' Takes Aim At PBM 'Kickbacks'
Trump's "Great Healthcare Plan" targets PBM kickbacks to cut costs. Experts confirm these fees act as an industry "vig" driving up prices.
10 months ago benzinga.com
Why Health Care ETFs Aren't Panicking Over Big Pharma's Price Cuts
Healthcare ETFs stay resilient as Big Pharma agrees to Medicaid drug price cuts. Here's what is cushioning ETFs despite pricing pressure.
11 months ago benzinga.com
Eli Lilly CEO Slams PBM 'Rent Taking', Says They Drove Insulin List Prices To $275: 'We Can Disintermediate Them Easily'
Eli Lilly CEO Dave Ricks slams PBM "rent taking" for driving $275 insulin price bubble and explains why he's ready to "disintermediate them."
1 year ago benzinga.com
Trump's 100% Drug Tariff Will Hit Americans, Economist Says Buyers 'Eat The Cost,' Not Foreign Firms
President Donald Trump's proposed 100% tariffs on foreign pharmaceuticals will ultimately be paid by American patients and insurers, not foreign drug companies, according to economist Justin Wolfers.
1 year ago benzinga.com
Mark Cuban Exposes How Wholesalers Force Pharmacies Into Near-Exclusive Deals, Detailing PBMs' 'Stranglehold' On Drug Pricing
Mark Cuban explains how PBMs & wholesalers force pharmacies into exclusive deals, creating a 'stranglehold' on prescription drug prices.
1 year ago benzinga.com
Mark Cuban Says Cutting PBM Fees Won't Reduce Pharmaceutical R&D Funding: 'Manufacturers Can Sell To Us For More'
Mark Cuban challenges the idea that high drug prices are necessary for R&D, PBMs take away from profits, leaving less for innovation.
1 year ago benzinga.com
Trump's Pharma Tariffs Can Hit Novo Nordisk, Says Barclays Expert, But It's 'Difficult' To Predict As Drugmakers Have 'Complex Supply Chains'
Barclays has said that it's hard to predict which firm would be affected the most by pharma tariffs, except for Novo Nordisk.
1 year ago benzinga.com
Trump Threatens 200% Pharma Tariffs, But Analyst Says This Stock Is Immune And Expected To 'Benefit' From Levies
Donald Trump's proposed 200% tariffs can squeeze the profit margins of pharma companies, but LLY is poised to "benefit" except for the rest.
1 year ago benzinga.com
Mark Cuban Corrects Elizabeth Warren As She Slams JNJ, PFE For Higher Prices And Zero Taxes On Big Pharma: 'PBMs Corrupt Healthcare'
A debate over the healthcare system erupted on X, pitting Mark Cuban against Elizabeth Warren over the root causes of soaring drug prices.
1 year ago benzinga.com
Trump Sparks New Chapter In Transatlantic Trade War: What The US Buys From Europe
Trump announced 50% tariffs on all EU imports starting June 1, citing high trade deficits and unfair barriers. Pharmaceutical products and cars most exposed.
1 year ago benzinga.com
Trump's Drug Price Order Hits PBMs Hardest: CVS, Cigna, UNH In Focus As Experts Highlight 'Racket,' Pricing Distortion
Trump signed an executive order to lower drug prices, which could hit pharmacy benefit managers (PBMs) hard. PBMs have come under scrutiny for opaque pricing practices. Mark Cuban calls PBMs a racket.
1 year ago benzinga.com
Are Your Health Care ETFs Safe? Trump's New Policies May Trigger Shockwaves Across Pharma Stocks
Pharma ETFs closely watched as Trump's drug policies stir market volatility. Funds offer sector exposure but differ in risk levels and growth potential.
1 year ago benzinga.com
ETF Shake-Up: UNH's Meltdown Meets LLY's Moonshot
Healthcare sector sees volatility due to UnitedHealth's earnings disappointment, but ETFs like XLV, IHE, and XPH still show resilience and pockets of strength.
1 year ago benzinga.com
Eli Lilly, AbbVie, Bristol Myers, Regeneron, And Other Pharma Companies Slide As Donald Trump Confirms Tariffs On Pharma Companies
Even as Donald Trump paused the reciprocal tariffs for 90 days, he later confirmed that pharmaceutical companies would face tariffs.
1 year ago benzinga.com
Biopharma: A 'Safe Haven' As Tariff Turmoil Rages On?
Biopharma is seen as a safe haven for investors due to its high-margin business model and flexibility in dealing with potential tariffs. Other key questions remain.
1 year ago benzinga.com
Ken Griffin's Citadel Places Big Short Bet Against GSK - Here's What It Means for Investors
Ken Griffin's Citadel hedge fund places £305M short bet against GSK, with skepticism over long-term pipeline and recent stock rally.
-
2 years ago benzinga.com
Organon Beats On Q1, Women's Health Leads the Charge
Organon reported 5% increase in Q1 2024 revenue of $1.622 billion, beating consensus. EPS of $1.22 and dividend of $0.28 declared.
-
3 years ago benzinga.com
Here Are The Best-Performing Industry ETFs And Major Stock Contributors In April
It's a good time to look at how the major U.S. stock industry ETFs performed this month, as April comes to an end. In April, we saw the broader U.S.
-
13 years ago benzinga.com
Interesting Similarities Among 2013's Top-Performing ETFs
Interesting Similarities Among 2013's Top-Performing ETFs
-
14 years ago benzinga.com
Viva Vivus, But Not In ETFs (VVUS, IBB, PJP)
Viva Vivus, But Not In ETFs (VVUS, IBB, PJP)
-
15 years ago benzinga.com
Fifteen Health Care ETFs Trading Near 52-Week Highs
Fifteen Health Care ETFs Trading Near 52-Week Highs
-
15 years ago benzinga.com
Twelve Health Care ETFs Trading Near 52-Week Highs
Twelve Health Care ETFs Trading Near 52-Week Highs